Metodologias colaborativas de construção coletiva: análise dos resultados do curso de gestão social de bacias hidrográficas no contexto do projeto TSGA II

TCC(graduação) - Universidade Federal de Santa Catarina. Centro Tecnológico. Engenharia Sanitária e Ambiental.O presente trabalho buscou refletir e apresentar os resultados do curso de Gestão Social de Bacias Hidrográficas (GSBH) realizado nos municípios de Araranguá, Chapecó e Braço do Norte, no contexto do programa de capacitação do Projeto Tecnologias Sociais para a Gestão da Água II (TSGA II) em Santa Catarina. A água é um bem essencial à vida, é um recurso natural limitado que está presente em praticamente todos os processos ecológicos e sociais. Ela é, portanto, um bem comum da humanidade, dotado de valor ecológico, social e econômico. Por isso, sua gestão deve ser feita de forma participativa, qualificada, mediadora e estratégica, buscando entender e valorizar os contextos das comunidades locais inseridas nas bacias hidrográficas e suas relações com o ambiente. Os objetivos específicos deste trabalho são: a) sistematizar os resultados obtidos em cada uma das regiões; b) registrar a experiência de capacitação do Projeto TSGA II na Gestão Social de Bacias Hidrográficas; c) apresentar o acordo inicial construído nas regiões; d) construir um quadro síntese dos resultados em cada uma das regiões; e e) elaborar um reflexão teórica e metodológica para o avanço das Tecnologias Sociais de Gestão da Água. Para isso, foram utilizadas metodologias colaborativas de construção coletiva de conceitos e estratégias, tais como: a Pedagogia do Amor, a metodologia de Construção do Espírito da Lei das Águas e sinergia com as Leis Irmãs e a metodologia Open Space ou Espaço Aberto. Como resultados desse trabalho tem-se a apresentação dos acordos iniciais construídos coletivamente e a construção de um quadro síntese dos resultados obtidos durante os cursos de GSBH nas regiões de Araranguá, Chapecó e Braço do Norte. A expectativa deste trabalho é contribuir para a gestão dos recursos hídricos nas respectivas bacias hidrográficas, buscando sistematizar e devolver os resultados do curso aos participantes do curso, comitês de bacias e lideranças locais

Programa computacional para a geração de dados para a modelagem em elementos finitos da continuidade posterior de lajes alveolares

03

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Um software para a avaliação do fck de elementos estruturais de concreto armado em ensaios esclerométricos

13

Um software para a avaliação do fck de elementos estruturais de concreto armado em ensaios esclerométricos

13